Medikinet® (methylphenidate hydrochloride) tablets
Medikinet® tablets can be used as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD) in children aged 6 years of age and over when remedial measures alone have proved insufficient. Medikinet tablets are not licensed for use in adults 18 years and over.1
Dosing & administration
- At the start of treatment with Medikinet® tablets, careful dose titration is necessary1
- Recommended starting daily dose is 5 mg once or twice daily e.g. at mealtimes1
- Dose can be increased if necessary by weekly increments of 5-10 mg daily, depending on how well it’s tolerated and working. The maximum daily dose of methylphenidate hydrochloride is 60 mg.1
- When treating ADHD, it helps to carefully choose the time treatment is taken so it combats any school or behavioural difficulties most effectively1
Safety and Monitoring
Access our full safety and monitoring information or please refer to section 4 of the SPC.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare Professionals are asked to report any suspected adverse reactions.
Date of Preparation: August 2024 UK-MIR-2024-1643-v2
Adverse event reporting
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to MEDICE UK, Medical Information Tel: 0204 582 2845, medicalinformation@medice.co.uk
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should be reported to MEDICE UK, Medical Information Tel: 0204 582 2845, medicalinformation@medice.co.uk